Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) from a strong sell rating to a sell rating in a report released on Saturday.
Several other equities analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.06.
Check Out Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Down 2.9%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the business earned ($0.41) EPS. Equities analysts predict that Recursion Pharmaceuticals will post -0.92 EPS for the current fiscal year.
Insider Activity
In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00. Following the transaction, the director directly owned 6,188,287 shares of the company’s stock, valued at approximately $20,111,932.75. This trade represents a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 131,937 shares of company stock worth $478,874. 6.65% of the stock is owned by insiders.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $31,000. Integral Investment Advisors Inc. acquired a new position in Recursion Pharmaceuticals during the first quarter worth $39,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $41,000. MQS Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the first quarter worth $41,000. Finally, Fund Advisors of America Inc FL purchased a new position in shares of Recursion Pharmaceuticals during the second quarter worth $45,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
